Mass Spectrometry Studies of DNA-Directed Alkylating Agents - Abdul Majid, Amin Malik Shah
51,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
26 °P sammeln
  • Broschiertes Buch

This work is focused on the use of Mass Spectrometry based technique to determine the site of drug binding and to observe the chemical reactions that occur during ligand-DNA interaction. Such approach is useful and has great potential in aiding DNA targeted drug design in terms of assessing the ligand DNA cross-linking ability, sequence specificity and to certain extent, degree of reactivity for a particular binding site. This work is part of a wider effort in developing drugs that target the minor groove region of the DNA which has been known to be invisible to DNA repair enzymes, a common…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This work is focused on the use of Mass Spectrometry based technique to determine the site of drug binding and to observe the chemical reactions that occur during ligand-DNA interaction. Such approach is useful and has great potential in aiding DNA targeted drug design in terms of assessing the ligand DNA cross-linking ability, sequence specificity and to certain extent, degree of reactivity for a particular binding site. This work is part of a wider effort in developing drugs that target the minor groove region of the DNA which has been known to be invisible to DNA repair enzymes, a common problem that leads to cancer drug resistance. Mass spectrometry has many advantages in comparison to the conventional techniques applied in DNA targeted drug design. It can provide detail insights into the chemistry of drug-DNA interactions at high level of accuracy and sensitivity.
Autorenporträt
Dr Amin Malik Shah is a Senior Lecturer at University Science Malaysia. He is also a researcher at University of New South Wales, Australia. His research interest is towards the understanding of how chemotherapeutic agents interact with the DNA. This knowledge can help to design anti-cancer agents that are more potent with fewer side effects.